Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Treasury Shares (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Treasury Shares for 12 consecutive years, with $400000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 83.33% year-over-year to $400000.0, compared with a TTM value of $400000.0 through Dec 2025, down 83.33%, and an annual FY2025 reading of $400000.0, down 83.33% over the prior year.
  • Treasury Shares was $400000.0 for Q4 2025 at Neurocrine Biosciences, down from $1.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.4 million in Q4 2023 and bottomed at $400000.0 in Q4 2025.
  • Average Treasury Shares over 3 years is $1.6 million, with a median of $1.5 million recorded in 2025.
  • The sharpest move saw Treasury Shares changed 0.0% in 2024, then crashed 83.33% in 2025.
  • Year by year, Treasury Shares stood at $2.4 million in 2023, then changed by 0.0% to $2.4 million in 2024, then plummeted by 83.33% to $400000.0 in 2025.
  • Business Quant data shows Treasury Shares for NBIX at $400000.0 in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.